To quantify and compare the histological components and architectural patterns of Gleason grades in cancerous areas with restriction on apparent diffusion coefficient (ADC) maps.
Twelve consecutive cases with 14 separate ADC restriction areas, positive for cancer in the peripheral zone (PZ) and transition zone (TZ) were included. All had 3 Tesla MRI and radical prostatectomy. Ten regions of interest (ROIs) within and outside the 14 ADC restriction areas positive for cancer were selected. For each ROI, we performed quantitative analysis of (a) prostate benign and malignant histological component surface ratios, including stroma, glands, epithelium, lumen, cellular nuclei; (b) percent of Gleason grades and measures of ADC values. Means of histological components according to ADC restriction for cancerous area were compared with analyses of variance with repeated measures.
Independent predictors of the probability of cancer were median epithelium/ROI ratio (P = 0.001) and nuclei/ROI ratio (P = 0.03). Independent predictors of the probability of ADC restriction were malignant glands/ROI and luminal space/ROI (P < 0.0001). Effect of malignant glands/ROI area was different according to the localization of the ROI (P = 0.03). We observed an overall difference between the means for all of the histological components for the comparison of true positive and false negative (P < 0.0001), except for the percent of Gleason grade 4 (P = 0.18). In TZ cancers, a predominant grade 3 pattern was associated with low ADC values. In PZ cancers, a predominant grade 4 pattern was associated with low ADC values.
Determinants of low ADC were high ratio of malignant glands/ROI area which may be seen in Gleason grades 3 or 4 cancers.
3 J. Magn. Reson. Imaging 2017.
Journal of magnetic resonance imaging : JMRI. 2017 Apr 06 [Epub ahead of print]
Olivier Helfrich, Philippe Puech, Nacim Betrouni, Claire Pinçon, Adil Ouzzane, Jérome Rizk, Gauthier Marcq, Marco Randazzo, Matthieu Durand, Said Lakroum, Xavier Leroy, Arnauld Villers
Department of Urology, CHRU Lille, Lille university, Lille, France., Inserm, U1189 - ONCO-THAI, CHRU Lille, Lille university, France., EA 2694 - Lille university, Santé publique: épidémiologie et qualité des soins, Lille, France., Department of Urology, University Hospital Zürich, Zürich, Switzerland., Department of Urology, CHU Nice, Nice-Sophia-Antipolis University, France., Department of Pathology, CHRU Lille, Lille university, Lille, France.